Rotigotine: Restless Legs Syndrome

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@kumc.edu.

Get full access to this article

View all access options for this article.

References

Hening

W.A.

Current guidelines and standards of practice for restless legs syndrome. Am J Med. 2007; 120(1A): S22–27.

Hening

W.A.

, Allen

R.P.

, Earley

C.J.

, Picchietti

D.L.

, Silber

M.H.

An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004; 27(3): 560–583.

Vignatelli

, Billiard

, Clarenach

EFNS guidelines on the management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol. 2006; 13: 1049–1065.

Trenkwalder

, Benes

, Poewe

Efficacy of rotigotine for treatment of moderate to severe restless legs syndrome: a randomized, double-blind, placebo controlled trial. Lancet Neurol. 2008; 7: 595–604.

Oertel

W.H.

, Benes

, Garcia-Borreguero

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double blind, placebo controlled, six-week dose finding trail in Europe. Sleep Med. 2008; 9: 228–239.

Oertel

W.H.

, Benes

, Garcia-Borreguero

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med. 2008; 9: 865–873.